New research from Paris-based biotech endogene.bio suggests endometriosis is molecularly heterogeneous across patients, lesion sites, and cell types. 

This molecular heterogeneity has important implications for how endometriosis treatments are studied and developed.  

Treating the disease as a single entity may help explain why many clinical trials yield mixed results or fail, while matching patients to therapies based on biology could improve trial success and efficiency. 

The researchers combined single-cell RNA sequencing with a computational drug-response framework. The approach focuses on the specific cell populations most likely to drive lesion persistence, rather than averaging signals across an entire tissue. 

For single-cell datasets spanning eutopic endometrium and endometriotic lesions, the analysis identified disease-associated molecular mechanisms concentrated in stromal, endothelial, and stem-like cell populations, which consistently showed disease-associated transcriptional changes linked to lesion maintenance.  

The model then predicted which therapeutic mechanisms may be most likely to counter these disease states and identifies responder subgroups, suggesting that a drug effective for one subset of patients may be less relevant for another. 

Dr Cristina Fernández Molina, Co-Founder and Head of Science at endogene.bio, commented: “Endometriosis is currently classified based on symptoms and anatomical or surgical features, but these approaches don’t capture the biological programs active inside the tissue. Our work shows that what looks like unpredictable variability between patients actually reflects recurring cellular states that shape how the disease behaves and responds to treatment. This creates an opportunity to move toward more biologically informed patient stratification in research and clinical trials.” 

The findings add to a growing body of evidence that endometriosis is not one disorder but many, each driven by distinct cellular programs and therapeutic vulnerabilities. This shift suggests that clinical trials enrolling biologically defined subgroups may be more informative, less ambiguous and less likely to fail late.

Diana Turner, Deputy Editor, DDW